By Colin Kellaher 



  Johnson & Johnson on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its investigational Ebola vaccine regimen for the prevention of the disease caused by the Zaire ebolavirus species. 


  J&J said the two-dose regimen is designed to support preventive vaccination in countries that are at risk of Ebola outbreaks, as well as for other at-risk groups, such as healthcare and lab workers. 


  The company said the regimen includes Ad26.ZEBOV as the first dose, based on its Janssen Pharmaceutical Cos. unit's proprietary AdVac viral vector technology, and MVA-BN-Filo as the second dose, based on Bavarian Nordic A/S's MVA-BN  technology, administered roughly eight weeks later. 


  "Today's CHMP opinion confirms the potential of Janssen's vaccine technology, which we hope to apply against a range of established and emerging epidemic threats, including the Covid-19 pandemic," J&J said. 


  The regimen now awaits approval from the European Commission, which generally follows the CHMP's recommendations. 


  Write to Colin Kellaher at colin.kellaher@wsj.com